

Supporting Information

From Benzopyrroles to Phenylpyrroles: Remodeling of Indoles Enabled by Photoredox Catalysis

Wei Xu,^{a,b} Bin Cheng,^{*a} Yaoge Zhang,^c Lijing Fang,^b Hongbin Zhai,^d Cuiping Wang^{*c}
and Taimin Wang^{*a}

^a *Institute of Marine Biomedicine, Shenzhen Polytechnic, Shenzhen, 518055, China.*

^b *Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology,
Chinese Academy of Sciences, Shenzhen, 518055, China*

^c *School of Chemical Engineering, University of Science and Technology Liaoning, Anshan
114051, China*

^d *State Key Laboratory of Chemical Oncogenomics, Peking University Shenzhen Graduate
School, Shenzhen 518055, China*

E-mails: chengbin@szpt.edu.cn

wangtm@szpt.edu.cn

cuiping1025@126.com


Contents

| | |
|---|-----------|
| General Information..... | 1 |
| General Synthesis of <i>N</i>-Sulfonyl-3-Acyl Indoles..... | 1 |
| Characterization data of unknown substrates..... | 2 |
| Photochemical set-up..... | 9 |
| Optimization of reaction conditions..... | 11 |
| General procedure for the synthesis of 3-(<i>o</i>-aminophenyl)pyrroles..... | 13 |
| Mechanistic investigation..... | 14 |
| Characterization data of products..... | 16 |
| Copies of NMR spectra of unknown substrates and products..... | 29 |

General Information

Reagents were purchased from commercial sources and were used as received unless otherwise noted. Anhydrous CH_2Cl_2 was refluxed with CaH_2 and freshly distilled prior to use. Ultradry *N,N*-dimethylformamide was used as obtained from commercial sources without further purification. Proton and carbon magnetic resonance spectra (^1H NMR and ^{13}C NMR) were recorded on a *JEOL-400YH* (^1H NMR at 400 MHz, ^{13}C NMR at 100 MHz and ^{19}F NMR at 376 MHz) spectrometer with tetramethylsilane (TMS) or deuterated solvent resonance as the internal standard (^1H NMR: TMS at 0.00 ppm; ^{13}C NMR: CDCl_3 at 77.0 ppm). All spectra are reported as parts per million. ^1H , ^{13}C and ^{19}F NMR data are reported as follows: chemical shift (ppm), multiplicity (app = apparent, s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, dd = doublet of doublets, td = triplet of doublets, ddd = double of doublet of doublets, m = multiplet), coupling constants (Hz), and integration. High Resolution Mass Spectra (HRMS) were performed by Analytical Instrument Center at the State Key Laboratory of Chemical Oncogenomics of Peking University Shenzhen Graduate School on an Electron Spray Injection (ESI) mass spectrometer. Melting point was recorded on an SGW® X-4A melting point apparatus.

General Synthesis of *N*-Sulfonyl-3-Acyl Indoles




Commercially unavailable 3-acyl indoles **S2** were prepared via acylation of indoles following the practical protocol developed by Ottoni's group in 2001 (Ref: *Org. Lett.* **2001**, 3, 1005-1007), and used directly for *N*-sulfonylation without any purification.

To a solution of indole **S1** (1.0 eq.) in anhydrous DCM at $0\text{ }^\circ\text{C}$ under N_2 was added SnCl_4 (1.5 eq.) in a single portion via syringe. After the ice bath was removed, the mixture was stirred vigorously at room temperature for 30 min, and then acyl chloride (R^2COCl , 1.2 eq.) was added in small portions to the dark suspension, followed by the addition of MeNO_2 . The reaction was quenched with cold water after it was stirred for 2 h at room temperature. Then the mixture was filtered under reduced pressure and the filtrate was extracted with ethyl acetate for three times. The combined organic phases were dried over anhydrous Na_2SO_4 and concentrated *in vacuo*, and the residue was used directly for next step.

The crude 3-acyl indole **S2** was suspended in DCM , then DMAP (0.1 eq.) and sulfonyl chloride ($\text{R}^1\text{SO}_2\text{Cl}$, 2.0 eq.) were added, followed by the addition of triethylamine (3.0 eq.) via

syringe at room temperature. The resulting mixture was stirred for 0.5–12 h for full consumption of 3-acyl indole **S2**, according to the result monitored by TLC. The volatile was carefully removed *in vacuo* before ethyl acetate was added, and the mixture was stirred vigorously for 10 min, then filtered. The filtrate was concentrated *in vacuo* to give a residue, which was purified through column chromatography with petroleum/ether ethyl acetate as the eluent to give the titled product **1**.


Characterization data of unknown substrates



1c

1-(1-(mesitylsulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1c**)


white powder, **M. p.** = 112–113 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.36 (dt, *J* = 8.1, 1.1 Hz, 1H), 8.32 (s, 1H), 7.33–7.27 (m, 1H), 7.25–7.18 (m, 2H), 6.98 (s, 2H), 2.58 (s, 3H), 2.54 (s, 6H), 2.29 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.5, 144.9, 140.3, 134.7, 132.7, 132.6, 131.6, 127.1, 125.3, 124.4, 123.1, 119.5, 111.8, 27.7, 22.5, 21.0; **HRMS** (ESI) *m/z*: calcd for C₁₉H₂₀NO₃S⁺ [M+H]⁺, 342.1158; found, 342.1156;



1d

1-(1-((2,4,6-triisopropylphenyl)sulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1d**)


white powder, **M. p.** = 137–139 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.35 (dt, *J* = 8.0, 1.1 Hz, 1H), 8.26 (s, 1H), 7.32–7.27 (m, 1H), 7.25–7.17 (m, 4H), 4.16 (sept, *J* = 6.8 Hz, 2H), 2.91 (sept, *J* = 6.9 Hz, 1H), 2.58 (s, 3H), 1.24 (d, *J* = 6.9 Hz, 6H), 1.12 (d, *J* = 6.8 Hz, 12H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.4, 155.4, 151.5, 135.0, 131.6, 130.3, 126.9, 125.2, 124.5, 124.3, 123.0, 120.1, 111.9, 34.2, 29.6, 27.7, 24.3, 23.3; **HRMS** (ESI) *m/z*: calcd for C₂₅H₃₂NO₃S⁺ [M+H]⁺, 426.2097; found, 426.2108;



1f

1-(1-((2-fluorophenyl)sulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1f**)


white powder, **M. p.** = 115–117 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.38–8.32 (m, 2H), 8.14 (ddd, *J* = 7.9, 7.1, 1.8 Hz, 1H), 7.79–7.71 (m, 1H), 7.62–7.52 (m, 1H), 7.36–7.27 (m, 3H), 7.09 (ddd, *J* = 10.2, 8.4, 1.1 Hz, 1H), 2.59 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.4, 158.9 (d, *J* = 259.1 Hz), 137.1 (d, *J* = 8.8 Hz), 134.4, 133.0 (d, *J* = 2.9 Hz), 130.3, 127.3, 125.5, 125.2 (d, *J* = 13.3 Hz), 124.8, 124.7, 123.0, 121.0, 117.6 (*J* = 20.7 Hz), 112.6, 27.6; **¹⁹F NMR** (376 MHz, CDCl₃): δ -107.4 (m, 1F); **HRMS** (ESI) *m/z*: calcd for C₁₆H₁₃FNO₃S⁺ [M+H]⁺, 318.0595; found, 318.0591;



1h

1-(1-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1h**)

white powder, **M. p.** = 161–163 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.40 (s, 2H), 8.34 (d, *J* = 7.1 Hz, 1H), 8.18 (s, 1H), 8.10 (s, 1H), 7.94 (d, *J* = 8.0 Hz, 1H), 7.49–7.34 (m, 2H), 2.59 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.2, 140.0, 134.7, 133.6 (q, *J* = 34.9 Hz), 131.3, 128.2 (q, *J* = 3.6 Hz), 127.7, 127.2 (q, *J* = 3.8 Hz), 126.5, 125.6, 123.6, 123.0, 122.0 (q, *J* = 273.6 Hz), 112.6, 27.9; **¹⁹F NMR** (376 MHz, CDCl₃): δ -63.0 (s, 6F); **HRMS** (ESI) *m/z*: calcd for C₁₈H₁₂F₆NO₃S⁺ [M+H]⁺, 436.0437; found, 436.0433;




1i

1-(1-((2,4-dichlorophenyl)sulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1i**)


white powder, **M. p.** = 102–104 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.40–8.34 (m, 2H), 8.28 (d, *J* = 8.5 Hz, 1H), 7.58–7.54 (m, 1H), 7.52–7.45 (m, 2H), 7.35 (td, *J* = 7.6, 1.2 Hz, 1H), 7.30 (ddd, *J* =

8.6, 7.3, 1.4 Hz, 1H), 2.60 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 193.4, 141.9, 134.4, 133.91, 133.87, 133.5, 132.8, 132.5, 127.9, 127.5, 125.7, 125.1, 123.5, 120.7, 112.4, 27.8; HRMS (ESI) m/z : calcd for $\text{C}_{16}\text{H}_{12}\text{Cl}_2\text{NO}_3\text{S}^+$ $[\text{M}+\text{H}]^+$, 367.9909; found, 367.9908;




1-(1-(benzylsulfonyl)-1*H*-indol-3-yl)ethan-1-one (**11**)

white powder, **M. p.** = 104–106 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.41–8.34 (m, 1H), 7.88–7.80 (m, 1H), 7.44–7.36 (m, 3H), 7.33–7.27 (m, 1H), 7.17 (t, J = 7.8 Hz, 2H), 6.86–6.78 (m, 2H), 4.56 (s, 2H), 2.29 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 193.4, 135.2, 133.5, 130.3, 129.6, 128.8, 127.1, 126.2, 125.8, 124.9, 123.2, 120.2, 112.6, 59.8, 27.4; HRMS (ESI) m/z : calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_3\text{S}^+$ $[\text{M}+\text{H}]^+$, 314.0845; found, 314.0843;




1-(1-(mesitylsulfonyl)-4-methyl-1*H*-indol-3-yl)ethan-1-one (**1p**)

light yellow crystal, **M. p.** = 143–144 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.32 (s, 1H), 7.12–7.06 (m, 1H), 7.06–6.99 (m, 2H), 6.96 (s, 2H), 2.71 (s, 3H), 2.61 (s, 3H), 2.52 (s, 6H), 2.27 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 193.1, 144.8, 140.2, 135.3, 134.0, 133.1, 132.6, 131.7, 126.4, 125.8, 125.3, 121.8, 109.3, 29.0, 22.7, 22.5, 21.0; HRMS (ESI) m/z : calcd for $\text{C}_{20}\text{H}_{22}\text{NO}_3\text{S}^+$ $[\text{M}+\text{H}]^+$, 356.1315; found, 356.1323;




1-(1-(mesitylsulfonyl)-5-methyl-1*H*-indol-3-yl)ethan-1-one (**1q**)

brown powder, **M. p.** = 142–144 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.28 (s, 1H), 8.16 (dt, J = 1.8, 0.8 Hz, 1H), 7.10–7.01 (m, 2H), 6.97 (s, 2H), 2.57 (s, 3H), 2.53 (s, 6H), 2.41 (s, 3H), 2.29 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 193.7, 144.8, 140.3, 134.3, 132.9, 132.8, 132.6, 131.7, 127.3, 126.7, 122.9, 119.3, 111.4, 27.7, 22.5, 21.3, 21.0; HRMS (ESI) m/z : calcd for $\text{C}_{20}\text{H}_{22}\text{NO}_3\text{S}^+$ $[\text{M}+\text{H}]^+$, 356.1315; found, 356.1309;




1-(1-(mesitylsulfonyl)-6-methyl-1*H*-indol-3-yl)ethan-1-one (**1r**)

clear crystal, **M. p.** = 166–168 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.24–8.18 (m, 2H), 7.13 (ddd, *J* = 8.1, 1.5, 0.7 Hz, 1H), 7.04 (dt, *J* = 1.6, 0.8 Hz, 1H), 6.99 (s, 2H), 2.56 (s, 3H), 2.55 (s, 6H), 2.35 (s, 3H), 2.31 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.6, 144.9, 140.3, 135.5, 135.2, 132.6, 132.2, 131.8, 126.0, 124.8, 122.7, 119.7, 112.0, 27.7, 22.6, 21.9, 21.1; **HRMS** (ESI) *m/z*: calcd for C₂₀H₂₂NO₃S⁺ [M+H]⁺, 356.1315; found, 356.1318;




1-(5-fluoro-1-(mesitylsulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1s**)

white powder, **M. p.** = 154–155 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.32 (s, 1H), 8.05 (dd, *J* = 9.2, 2.6 Hz, 1H), 7.14 (dd, *J* = 9.0, 4.3 Hz, 1H), 7.00 (s, 2H), 6.96 (td, *J* = 9.0, 2.6 Hz, 1H), 2.57 (s, 3H), 2.54 (s, 6H), 2.31 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.2, 160.3 (d, *J* = 241.4 Hz), 145.2, 140.3, 133.9, 132.7, 131.4, 131.0, 128.3 (d, *J* = 11.0 Hz), 119.4 (d, *J* = 4.2 Hz), 113.6 (d, *J* = 26.1 Hz), 112.8 (d, *J* = 9.4 Hz), 108.9 (d, *J* = 25.2 Hz), 27.6, 22.6, 21.1; **¹⁹F NMR** (376 MHz, CDCl₃): δ -117.6 (m, 1F); **HRMS** (ESI) *m/z*: calcd for C₁₉H₁₉FNO₃S⁺ [M+H]⁺, 360.1064; found, 360.1076;




1-(5-chloro-1-(mesitylsulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1t**)

brown powder, **M. p.** = 160–162 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.37 (d, *J* = 2.0 Hz, 1H), 8.30 (s, 1H), 7.18 (dd, *J* = 8.9, 2.1 Hz, 1H), 7.12 (dd, *J* = 8.8, 0.7 Hz, 1H), 6.99 (s, 2H), 2.57 (s, 3H), 2.52 (s, 6H), 2.30 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.1, 145.2, 140.3, 133.5, 133.0, 132.7, 131.3, 130.5, 128.2, 125.7, 122.8, 118.9, 112.8, 27.6, 22.5, 21.0; **HRMS** (ESI) *m/z*: calcd for C₁₉H₁₉ClNO₃S⁺ [M+H]⁺, 376.0769; found, 376.0776;




1-(5-bromo-1-(mesitylsulfonyl)-1*H*-indol-3-yl)ethan-1-one (**1u**)

brown powder, **M. p.** = 178–179 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.53 (d, *J* = 2.0 Hz, 1H), 8.28 (s, 1H), 7.31 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.07 (d, *J* = 8.8 Hz, 1H), 6.99 (s, 2H), 2.57 (s, 3H), 2.52 (s, 6H), 2.30 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.1, 145.2, 140.3, 133.4, 133.3, 132.7, 131.3, 128.7, 128.3, 125.8, 118.8, 118.2, 113.2, 27.6, 22.5, 21.0; **HRMS** (ESI) *m/z*: calcd for C₁₉H₁₉BrNO₃S⁺ [M+H]⁺, 420.0264; found, 420.0258;




3-acetyl-1-(mesitylsulfonyl)-1*H*-indole-5-carbonitrile (**1v**)

brown powder, **M. p.** = 190–192 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.75 (dd, *J* = 1.7, 0.8 Hz, 1H), 8.38 (s, 1H), 7.48 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.32 (dd, *J* = 8.7, 0.8 Hz, 1H), 7.03 (s, 2H), 2.60 (s, 3H), 2.54 (s, 6H), 2.33 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 192.9, 145.7, 140.4, 136.3, 134.1, 132.9, 131.0, 128.4, 128.3, 127.2, 119.0, 118.9, 112.9, 108.2, 27.7, 22.6, 21.1; **HRMS** (ESI) *m/z*: calcd for C₂₀H₁₉N₂O₃S⁺ [M+H]⁺, 367.1111; found, 367.1122;




methyl 3-acetyl-1-(mesitylsulfonyl)-1*H*-indole-5-carboxylate (**1w**)

offwhite powder, **M. p.** = 155–157 °C; **¹H NMR** (400 MHz, CDCl₃): δ 9.04 (d, *J* = 1.8 Hz, 1H), 8.38 (s, 1H), 7.94 (dd, *J* = 8.8, 1.7 Hz, 1H), 7.26 (d, *J* = 8.8 Hz, 1H), 6.99 (s, 2H), 3.91 (s, 3H), 2.62 (s, 3H), 2.53 (s, 6H), 2.29 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.0, 166.8, 145.2, 140.2, 137.0, 133.6, 132.6, 131.2, 126.8, 126.6, 126.4, 125.2, 119.7, 111.6, 52.0, 27.7, 22.4, 21.0; **HRMS** (ESI) *m/z*: calcd for C₂₁H₂₂NO₅S⁺ [M+H]⁺, 400.1213; found, 400.1212;




1-(1-(mesitylsulfonyl)-5-methoxy-1*H*-indol-3-yl)ethan-1-one (**1x**)

gray powder, **M. p.** = 144–146 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.27 (s, 1H), 7.85 (d, *J* = 2.5 Hz, 1H), 7.07 (dd, *J* = 8.9, 0.6 Hz, 1H), 6.98 (s, 2H), 6.83 (dd, *J* = 9.0, 2.6 Hz, 1H), 3.84 (s, 3H), 2.57 (s, 3H), 2.53 (s, 6H), 2.30 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.7, 157.3, 144.9, 140.3, 133.1, 132.7, 131.7, 129.3, 128.2, 119.4, 115.3, 112.6, 104.5, 55.7, 27.6, 22.5, 21.1; **HRMS** (ESI) *m/z*: calcd for C₂₀H₂₂NO₄S⁺ [M+H]⁺, 372.1264; found, 372.1260;




1-(1-(mesitylsulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)ethan-1-one (**1y**)

white powder, **M. p.** = 133–134 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.56 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.49 (s, 1H), 8.26 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.21 (dd, *J* = 7.9, 4.7 Hz, 1H), 6.96 (s, 2H), 2.71 (s, 6H), 2.60 (s, 3H), 2.27 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 193.3, 147.3, 145.8, 144.7, 141.3, 132.2, 132.0, 131.4, 131.3, 120.1, 119.7, 117.6, 27.2, 22.8, 21.0; **HRMS** (ESI) *m/z*: calcd for C₁₈H₁₉N₂O₃S⁺ [M+H]⁺, 343.1111; found, 343.1123;



1-(1-(mesitylsulfonyl)-2-methyl-1*H*-indol-3-yl)ethan-1-one (**1z**)


brown powder, **M. p.** = 124–126 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.17–8.09 (m, 1H), 7.97–7.88 (m, 1H), 7.34–7.27 (m, 2H), 6.95 (s, 2H), 2.64 (s, 3H), 2.57 (s, 3H), 2.38 (s, 6H), 2.29 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 195.9, 144.4, 142.9, 139.6, 136.6, 134.4, 132.3, 125.7, 124.4, 123.7, 120.7, 119.3, 114.7, 32.1, 22.2, 21.0, 13.0; **HRMS** (ESI) *m/z*: calcd for C₂₀H₂₂NO₃S⁺ [M+H]⁺, 356.1315; found, 356.1311;



1-(1-(mesitylsulfonyl)-1*H*-indol-3-yl)propan-1-one (**1A**)


brown powder, **M. p.** = 131–133 °C; **¹H NMR** (400 MHz, CDCl₃): δ 8.38 (dt, *J* = 8.0, 1.1 Hz, 1H), 8.34 (s, 1H), 7.33–7.27 (m, 1H), 7.23–7.17 (m, 2H), 6.97 (s, 2H), 2.95 (q, *J* = 7.4 Hz, 2H), 2.54 (s, 6H), 2.28 (s, 3H), 1.26 (t, *J* = 7.4 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 196.8, 144.9, 140.2, 134.6, 132.6, 132.0, 131.7, 127.3, 125.2, 124.3, 123.1, 118.8, 111.8, 33.1, 22.5, 21.0, 8.4; **HRMS**

(ESI) m/z : calcd for $C_{20}H_{22}NO_3S^+$ $[M+H]^+$, 356.1315; found, 356.1325;




1-(1-(mesitylsulfonyl)-1*H*-indol-3-yl)butan-1-one (**1B**)

colorless crystal, **M. p.** = 131–133 °C; 1H NMR (400 MHz, $CDCl_3$): δ 8.38 (dt, J = 8.0, 1.1 Hz, 1H), 8.34 (s, 1H), 7.33–7.27 (m, 1H), 7.24–7.17 (m, 2H), 6.97 (s, 2H), 2.89 (t, J = 7.4 Hz, 2H), 2.54 (s, 6H), 2.28 (s, 3H), 1.87–1.76 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 196.4, 144.9, 140.2, 134.6, 132.6, 132.2, 131.7, 127.3, 125.2, 124.4, 123.2, 119.2, 111.8, 41.9, 22.5, 21.0, 18.1, 13.9; **HRMS** (ESI) m/z : calcd for $C_{21}H_{24}NO_3S^+$ $[M+H]^+$, 370.1471; found, 370.1471;




1-(1-(mesitylsulfonyl)-1*H*-indol-3-yl)hexan-1-one (**1C**)

colorless crystal, **M. p.** = 115–117 °C; 1H NMR (400 MHz, $CDCl_3$): δ 8.38 (dt, J = 8.0, 1.1 Hz, 1H), 8.32 (s, 1H), 7.31 (ddd, J = 8.1, 6.5, 1.8 Hz, 1H), 7.24–7.17 (m, 2H), 6.99 (s, 2H), 2.90 (t, J = 7.2 Hz, 2H), 2.54 (s, 6H), 2.30 (s, 3H), 1.84–1.73 (m, 2H), 1.44–1.32 (m, 4H), 0.97–0.87 (m, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 196.7, 144.9, 140.3, 134.7, 132.7, 132.2, 131.8, 127.4, 125.3, 124.4, 123.3, 119.2, 111.8, 40.1, 31.6, 24.5, 22.6, 22.5, 21.1, 13.9; **HRMS** (ESI) m/z : calcd for $C_{23}H_{28}NO_3S^+$ $[M+H]^+$, 398.1784; found, 398.1786;



cyclohexyl(1-(mesitylsulfonyl)-1*H*-indol-3-yl)methanone (**1D**)

white powder, **M. p.** = 156–158 °C; 1H NMR (400 MHz, $CDCl_3$): δ 8.38 (dt, J = 8.0, 1.1 Hz, 1H), 8.35 (s, 1H), 7.30 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.23–7.12 (m, 2H), 6.98 (s, 2H), 3.07 (tt, J = 11.7, 3.3 Hz, 1H), 2.54 (s, 6H), 2.30 (s, 3H), 1.99–1.83 (m, 4H), 1.81–1.71 (m, 1H), 1.67–1.55 (m, 2H), 1.49–1.37 (m, 2H), 1.31 (tt, J = 12.3, 3.2 Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 200.1, 144.9, 140.3, 134.7, 132.7, 131.9, 131.8, 127.8, 125.3, 124.4, 123.4, 118.0, 111.7, 48.0, 29.7, 25.9, 25.8, 22.6, 21.1; **HRMS** (ESI) m/z : calcd for $C_{24}H_{28}NO_3S^+$ $[M+H]^+$, 410.1784; found, 410.1785



2,2,2-trifluoro-1-(1-(mesitylsulfonyl)-1H-indol-3-yl)ethan-1-one (**1E**)

colorless crystal, **M. p.** = 116–118 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.54 (q, *J* = 1.7 Hz, 1H), 8.36 (dt, *J* = 8.0, 1.0 Hz, 1H), 7.38 (ddd, *J* = 8.1, 7.0, 1.4 Hz, 1H), 7.30 (td, *J* = 8.4, 1.4 Hz, 1H), 7.28–7.23 (m, 1H), 7.01 (s, 2H), 2.56 (s, 6H), 2.31 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 176.0 (q, *J* = 36.3 Hz), 145.5, 140.5, 135.7 (q, *J* = 5.1 Hz), 134.3, 132.9, 131.1, 127.2, 126.3, 125.3, 122.8, 116.4 (q, *J* = 290.9 Hz), 112.2, 111.8, 22.6, 21.1; ¹⁹F NMR (376 MHz, CDCl₃): δ -72.8 (s, 3F); **HRMS** (ESI) *m/z*: calcd for C₁₉H₁₇F₃NO₃S⁺ [M+H]⁺, 396.0876; found, 396.0869;

Photochemical set-up

All the photoreactions were carried out using ROGER OHSP-350UV parallel photoreactor (provided by Beijing Nuozhi Technology Co., Ltd) equipped with 10 W blue LED for each reaction site, with a circling ethanol-cooled jacket. Light type of light reactor is 3A3A4100–455 nm from Nuozhi Technology.






Figure S1 The photochemical set-up

The emission spectrum (see below) of the blue LED reactor shows a maximum intensity at a wavelength of $\lambda(\text{emission})_{\text{max}} = 453.0 \text{ nm}$. The photophysical data of LEDs (Figure S2) was provided by Beijing Nuozhi Technology Co., Ltd.





Figure S2 Photophysical property of LEDs used during our exploration

Optimization of reaction conditions^a



| entry | PC | solvent | base | additive | yield of 3aa (%) ^b |
|-------|--|---------|--------------------------------|----------|--------------------------------------|
| 1 | 4CzIPN (PC1) | MeCN | K ₂ CO ₃ | none | 29 |
| 2 | <i>fac</i> -Ir(ppy) ₃ (PC2) | MeCN | K ₂ CO ₃ | none | N.D. |
| 3 | [Ir(dF(CF ₃)ppy) ₂ (5,5'-di-CF ₃ bpy)]PF ₆ (PC3) | MeCN | K ₂ CO ₃ | none | 29 |
| 4 | [Ir(dFppy) ₂ (dtbbpy)]PF ₆ (PC4) | MeCN | K ₂ CO ₃ | none | 22 |
| 5 | [Ir(Me(Me)ppy) ₂ (dtbbpy)]PF ₆ (PC5) | MeCN | K ₂ CO ₃ | none | 22 |
| 6 | [Ir(ppy) ₂ (dtbbpy)]PF ₆ (PC6) | MeCN | K ₂ CO ₃ | none | 18 |
| 7 | [Ir(dF(CF ₃)ppy) ₂ (dtbbpy)]PF ₆ (PC7) | MeCN | K ₂ CO ₃ | none | 32 |
| 8 | [Ir(dF(CF ₃)ppy) ₂ (bpy)]PF ₆ (PC8) | MeCN | K ₂ CO ₃ | none | 37 (37) ^c |
| 9 | <i>fac</i> -(<i>p</i> -CF ₃ -ppy) ₃ (PC9) | MeCN | K ₂ CO ₃ | none | N.D. |
| 10 | 4DPAIPN (PC10) | MeCN | K ₂ CO ₃ | none | 9.7 |
| 11 | 3DPA2FBN (PC11) | MeCN | K ₂ CO ₃ | none | N.D. |
| 12 | DPZ (PC12) | MeCN | K ₂ CO ₃ | none | 9.8 |
| 13 | CsPbBr ₃ (PC13) | MeCN | K ₂ CO ₃ | none | N.D. |
| 14 | PC8 | DCE | K ₂ CO ₃ | none | 18 |
| 15 | PC8 | THF | K ₂ CO ₃ | none | 12 |

| | | | | | |
|-----------------|------------|------------|------------------------------------|---------------------------------|----------------------------|
| 16 | PC8 | Dioxane | K ₂ CO ₃ | none | trace |
| 17 | PC8 | DMF | K ₂ CO ₃ | none | 62 |
| 18 | PC8 | DMSO | K ₂ CO ₃ | none | 47 |
| 19 | PC8 | MeOH | K ₂ CO ₃ | none | 27 |
| 20 | PC8 | DCM | K ₂ CO ₃ | none | 15 |
| 21 | PC8 | EtOAc | K ₂ CO ₃ | none | 17 |
| 22 | PC8 | PhMe | K ₂ CO ₃ | none | 13 |
| 23 | PC8 | DMC | K ₂ CO ₃ | none | N.D. |
| 24 | PC8 | DME | K ₂ CO ₃ | none | 19 |
| 25 | PC8 | Benzene | K ₂ CO ₃ | none | 18 |
| 26 | PC8 | DMF | K ₂ CO ₃ | Na ₂ SO ₄ | 62 |
| 27 | PC8 | DMF | K₂CO₃ | 4 Å MS | 76 (67)^d |
| 28 | PC8 | DMF | none | 4 Å MS | N.D. |
| 29 | PC8 | DMF | Li ₂ CO ₃ | 4 Å MS | 61 |
| 30 | PC8 | DMF | Na ₂ CO ₃ | 4 Å MS | 74 |
| 31 | PC8 | DMF | Cs ₂ CO ₃ | 4 Å MS | 58 |
| 32 | PC8 | DMF | NaOAc | 4 Å MS | 67 |
| 33 | PC8 | DMF | NaHCO ₃ | 4 Å MS | 38 |
| 34 | PC8 | DMF | K ₃ PO ₄ | 4 Å MS | 66 |
| 35 | PC8 | DMF | K ₂ HPO ₄ | 4 Å MS | 69 |
| 36 | PC8 | DMF | KH ₂ PO ₄ | 4 Å MS | 12 |
| 37 | PC8 | DMF | Na ₂ HPO ₄ | 4 Å MS | 15 |
| 38 | PC8 | DMF | NaOH | 4 Å MS | 13 |
| 39 | PC8 | DMF | Et ₃ N | 4 Å MS | 27 |
| 40 | PC8 | DMF | DIPEA | 4 Å MS | 22 |
| 41 | PC8 | DMF | DBU | 4 Å MS | 22 |
| 42 | none | DMF | K ₂ CO ₃ | 4 Å MS | 24 |
| 43 ^e | PC8 | DMF | K ₂ CO ₃ | 4 Å MS | N.D. |
| 44 ^f | PC8 | DMF | K ₂ CO ₃ | 4 Å MS | N.D. |

^aUnless otherwise specified, the reaction was conducted as follows: **1a** (0.1 mmol, 1equiv), **2a** (1.1 equiv), **PC** (1 mol %), base (1.5 equiv), additive (5 equiv of Na₂SO₄ or 50 mg of 4 Å MS, if used), solvent (1 mL), N₂, blue LEDs irradiation (10 W), rt, 24 h. ^bNMR yield was determined using 1,3,5-trimethoxybenzene as the internal standard. ^cIsolated yield. ^dIsolated yield on a 0.2 mmol scale of indole **1a**. ^eThe reaction was carried out in the dark. ^fThe reaction was conducted in the open air.





Figure S3 The structures of photocatalysts used for optimization of reaction conditions

General procedure for the synthesis of 3-(*o*-aminophenyl)pyrroles




To a 15-mL transparent glass vial with magnetic stir bar were successively added *N*-sulfonyl-3-acyl indole **1** (0.20 mmol), *N*-phenylglycine **2** (0.22 mmol), K₂CO₃ (41.4 mg, 0.30

mmol), 4 Å molecular sieve (100 mg), [Ir(dF(CF₃)ppy)(bpy)]PF₆ (**PC8**, 2.0 mg, 2 μmol) and anhydrous DMF (2 mL). The vial was then sealed up with the open-topped cap equipped with silicone septa and placed under N₂ atmosphere in the photoreactor under the irradiation of blue LED (455 nm, 10 W). The reaction was stirred for 24 h cooled with a circling chiller (ethanol as the refrigerant at 25 °C). Then the mixture was filtered *in vacuo* and washed with dichloromethane (2 mL×3). Then the filtrate was concentrated *in vacuo* to give a residue, which was purified through column chromatography with petroleum/ether ethyl acetate as the eluent to give 3-(2-aminophenyl)pyrrole **3**.


Mechanistic investigation

Radical trapping experiment with TEMPO



Two parallel reactions were performed. To a 15-mL transparent glass vial with magnetic stir bar were successively added *N*-sulfonyl-3-acyl indole **1a** (62.6 mg, 0.20 mmol), *N*-phenylglycine **2a** (33.3 mg, 0.22 mmol), K₂CO₃ (41.4 mg, 0.30 mmol), 4 Å molecular sieve (100 mg), [Ir(dF(CF₃)ppy)(bpy)]PF₆ (**PC8**, 2.0 mg, 2 μmol), TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy, 31.3 mg for 1.0 eq. and 62.5 mg for 2.0 eq.) and anhydrous DMF (2 mL) under N₂ atmosphere. The vial was then sealed up with the open-topped cap equipped with silicone septa and placed under N₂ in the photoreactor under the irradiation of blue LED (455 nm, 10 W). The reaction was stirred for 24 h cooled with a circling chiller (ethanol as the refrigerant at 25 °C). After that, internal standard 1,3,5-trimethoxybenzene (10.0 mg) was added to the reaction system and the resulting mixture was vigorously stirred for 20 min before being kept still for 20 min. A fraction of the reaction liquid (*ca.* 50 μL) was extracted and diluted with CDCl₃ (0.5 mL) for NMR analysis. The NMR yields of biaryl **3aa** were identified as 13% and 0% by the erosion of 1.0 and 2.0 equiv. of TEMPO, respectively.

Light on/off experiment



Six standard reactions were set up parallel on a 0.10 mmol scale with 1,3,5-trimethoxybenzene

(5.0 mg) as an internal standard. One of the reaction vials was unsealed for NMR analysis before the irradiation of the remained ones with blue LEDs for 2 h. Then the second parallel reaction was NMR analyzed and the remained four vials were kept in the dark for another 2 h. All the six parallel reactions were analyzed after alternant treatment with irradiation and darkness in a period of 2 h. The NMR yield of each reaction is listed as follows.

| Time (h) | 0 | 2 | 4 | 6 | 8 | 10 |
|-----------|-----|----|-----|----|-----|----|
| On/Off | Off | On | Off | On | Off | On |
| Yield (%) | 0 | 19 | 23 | 39 | 42 | 53 |





Figure S4 The results of the light on/off experiment

Emission Quenching Experiments (Stern–Volmer Studies)

Emission intensities were recorded using an FLS1000 Transient/Steady-state Fluorescence Spectrometer. The emission intensity was collected with the excitation wavelength at 480 nm. The fluorescence was measured from 470 nm to 800 nm. The fluorescence intensity for exploration of the relationship between I_0/I and the concentration of **1a/2a** was collected at maximum emission wavelength of 499 nm.







Figure S5 Stern–Volmer studies

- a:** The emission spectra of 5×10^{-5} M solutions of $[\text{Ir}(\text{dF}(\text{CF}_3)\text{ppy})_2(\text{bpy})]\text{PF}_6$ in DMF with (or without) different reaction components (blank, **1a**, **2a**, K_2CO_3 , 4 \AA molecular sieve);
- b:** The emission spectra of 5×10^{-5} M solutions of $[\text{Ir}(\text{dF}(\text{CF}_3)\text{ppy})_2(\text{bpy})]\text{PF}_6$ in DMF with various concentration of **1a**;
- c:** The emission spectra of 5×10^{-5} M solutions of $[\text{Ir}(\text{dF}(\text{CF}_3)\text{ppy})_2(\text{bpy})]\text{PF}_6$ in DMF with various concentration of **2a**;
- d:** The relationship between fluorescence quenching ratio (I_0/I) and the increasing concentration of **1a/2a**.

Characterization data of products




3aa

4-methyl-*N*-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3aa**)


54 mg (67%), yellowish powder, **M. p.** = 51–53 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.67 (dd, $J = 8.2, 1.2$ Hz, 1H), 7.61 (d, $J = 8.3$ Hz, 2H), 7.53–7.46 (m, 2H), 7.43–7.37 (m, 1H), 7.36–7.31 (m, 2H), 7.27–7.22 (m, 1H), 7.20–7.16 (m, 2H), 7.15–7.10 (m, 2H), 7.07 (td, $J = 7.4, 1.2$ Hz, 1H),

6.82 (d, $J = 2.9$ Hz, 1H), 5.87 (d, $J = 2.9$ Hz, 1H), 2.33 (s, 3H), 1.86 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 143.6, 139.9, 136.5, 135.2, 131.2, 129.5, 129.2, 127.8, 127.6, 127.4, 127.2, 127.1, 125.7, 124.0, 121.9, 119.2, 117.2, 108.8, 21.5, 11.0; HRMS (ESI) m/z : calcd for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 403.1475; found, 403.1492;




N-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**1ab**)

53 mg (68%), yellowish oil, ^1H NMR (400 MHz, CDCl_3): δ 7.75–7.67 (m, 3H), 7.53–7.45 (m, 3H), 7.42–7.35 (m, 3H), 7.35–7.30 (m, 2H), 7.25 (td, $J = 8.5, 1.9$ Hz, 1H), 7.16 (br s, 1H), 7.13 (dd, $J = 7.7, 1.9$ Hz, 1H), 7.08 (td, $J = 7.4, 1.2$ Hz, 1H), 6.81 (d, $J = 2.9$ Hz, 1H), 5.84 (d, $J = 2.9$ Hz, 1H), 1.83 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 139.8, 139.4, 135.0, 132.8, 131.2, 129.2, 128.8, 127.8, 127.7, 127.3, 127.1, 125.7, 124.2, 121.9, 119.4, 117.1, 108.7, 11.0 (1C is merged with other peaks); HRMS (ESI) m/z : calcd for $\text{C}_{23}\text{H}_{21}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 389.1318; found, 389.1332;



2,4,6-trimethyl-*N*-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3ac**)


61 mg (71%), offwhite powder, **M. p.** = 113–114 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.54–7.46 (m, 3H), 7.43–7.38 (m, 1H), 7.36–7.32 (m, 2H), 7.31 (br s, 1H), 7.23–7.13 (m, 2H), 7.06 (td, $J = 7.5, 1.3$ Hz, 1H), 6.86 (d, $J = 2.9$ Hz, 1H), 6.80 (s, 2H), 6.13 (d, $J = 2.9$ Hz, 1H), 2.42 (s, 6H), 2.19 (s, 3H), 1.84 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 142.2, 139.9, 139.3, 135.2, 133.9, 131.8, 131.2, 129.3, 127.8, 127.6, 127.3, 127.0, 125.6, 124.0, 121.8, 119.6, 117.6, 109.0, 22.8, 20.8, 11.0; HRMS (ESI) m/z : calcd for $\text{C}_{26}\text{H}_{27}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 431.1778; found, 431.1793



2,4,6-triisopropyl-*N*-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3ad**)


63 mg (61%), white powder, **M. p.** = 122–123 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.50–7.44 (m, 2H), 7.40–7.35 (m, 1H), 7.35–7.30 (m, 2H), 7.24 (dd, $J = 8.4, 1.3$ Hz, 1H), 7.19 (dd, $J = 7.5, 1.6$

Hz, 1H), 7.18–7.13 (m, 3H), 7.07 (br s, 1H), 7.05 (td, $J = 7.4, 1.3$ Hz, 1H), 6.84 (d, $J = 2.9$ Hz, 1H), 6.17 (d, $J = 2.9$ Hz, 1H), 4.12 (sept, $J = 6.8$ Hz, 2H), 2.89 (sept, $J = 6.8$ Hz, 1H), 2.01 (s, 3H), 1.24 (d, $J = 6.8$ Hz, 6H), 1.17 (d, $J = 6.8$ Hz, 12H); ^{13}C NMR (100 MHz, CDCl_3): δ 152.9, 150.3, 139.9, 135.8, 133.5, 131.4, 129.2, 127.42, 127.40, 127.2, 127.0, 125.7, 123.9, 123.5, 121.7, 118.9, 117.6, 109.2, 34.1, 29.8, 24.7, 23.5, 11.3; HRMS (ESI) m/z : calcd for $\text{C}_{32}\text{H}_{39}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 515.2727; found, 515.2744;




4-methoxy-*N*-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3ae**)

52 mg (62%), brown oil, ^1H NMR (400 MHz, CDCl_3): δ 7.71–7.61 (m, 3H), 7.52–7.45 (m, 2H), 7.42–7.36 (m, 1H), 7.36–7.32 (m, 2H), 7.24 (td, $J = 7.2, 1.8$ Hz, 1H), 7.17–7.11 (m, 2H), 7.07 (td, $J = 7.4, 1.2$ Hz, 1H), 6.86–6.80 (m, 3H), 5.89 (d, $J = 2.9$ Hz, 1H), 3.75 (s, 3H), 1.86 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 162.9, 139.8, 135.2, 131.2, 131.0, 129.24, 129.21, 127.7, 127.6, 127.3, 127.1, 125.7, 124.0, 121.8, 119.3, 117.2, 114.0, 108.7, 55.4, 11.0; HRMS (ESI) m/z : calcd for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}_3\text{S}^+$ $[\text{M}+\text{H}]^+$, 419.1424; found, 419.1458;




2-fluoro-*N*-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3af**)

44 mg (54%), yellowish powder, **M. p.** = 130–131 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.88 (td, $J = 7.5, 1.8$ Hz, 1H), 7.56 (d, $J = 8.2$ Hz, 1H), 7.53–7.44 (m, 4H), 7.43–7.35 (m, 3H), 7.23–7.14 (m, 3H), 7.09–6.98 (m, 2H), 6.87 (d, $J = 2.9$ Hz, 1H), 6.11 (d, $J = 2.9$ Hz, 1H), 1.91 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 158.9 (d, $J = 256.4$ Hz), 140.0, 135.2 (d, $J = 8.4$ Hz), 134.7, 131.3, 130.9, 129.2, 127.7, 127.5, 127.4, 127.2 (d, $J = 13.4$ Hz), 127.0, 125.8, 124.2 (d, $J = 3.8$ Hz), 124.0, 122.0, 118.5, 117.0 (d, $J = 2.2$ Hz), 116.8, 108.8, 11.0; ^{19}F NMR (376 MHz, CDCl_3): δ -109.4 (m, 1F); HRMS (ESI) m/z : calcd for $\text{C}_{23}\text{H}_{20}\text{FN}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 407.1224; found, 407.1224;




N-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)methanesulfonamide (**3aj**)

39 mg (59%), yellow oil, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (dd, $J = 8.2, 1.2$ Hz, 1H), 7.53–7.46 (m, 2H), 7.43–7.39 (m, 1H), 7.39–7.32 (m, 3H), 7.31–7.28 (m, 1H), 7.16 (td, $J = 7.5, 1.2$ Hz, 1H), 6.93 (br s, 1H), 6.89 (d, $J = 2.9$ Hz, 1H), 6.20 (d, $J = 2.9$ Hz, 1H), 2.96 (s, 3H), 2.08 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 139.8, 135.5, 131.7, 129.2, 128.2, 127.4, 127.2, 127.0, 125.8, 124.0, 122.2, 118.0, 117.3, 108.9, 39.3, 11.3; **HRMS** (ESI) m/z : calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 327.1162; found, 327.1159;




N-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)propane-1-sulfonamide (**3ak**)

34 mg (48%), brown oil, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (dd, $J = 8.2, 1.2$ Hz, 1H), 7.53–7.45 (m, 2H), 7.43–7.34 (m, 3H), 7.34–7.24 (m, 2H), 7.15 (td, $J = 7.5, 1.2$ Hz, 1H), 6.90 (br s, 1H), 6.89 (d, $J = 2.9$ Hz, 1H), 6.21 (d, $J = 2.9$ Hz, 1H), 3.08–2.99 (m, 2H), 2.08 (s, 3H), 1.79–1.68 (m, 2H), 0.97 (t, $J = 7.5$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 139.8, 135.6, 131.6, 129.2, 128.1, 127.4, 127.0, 126.8, 125.8, 123.7, 122.2, 117.8, 117.3, 108.8, 53.2, 17.0, 12.8, 11.2; **HRMS** (ESI) m/z : calcd for $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 355.1475; found, 355.1484;



N-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-1-phenylmethanesulfonamide (**3al**)


43 mg (54%), yellowish powder, **M. p.** = 50–52 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (dd, $J = 8.2, 1.2$ Hz, 1H), 7.49–7.43 (m, 2H), 7.40–7.35 (m, 1H), 7.34–7.25 (m, 7H), 7.22–7.18 (m, 2H), 7.14 (td, $J = 7.4, 1.2$ Hz, 1H), 6.84 (br s, 1H), 6.77 (d, $J = 2.9$ Hz, 1H), 5.93 (d, $J = 2.9$ Hz, 1H), 4.39 (s, 2H), 2.04 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 139.8, 135.6, 131.7, 130.6, 129.2, 128.8, 128.5, 128.0, 127.3, 127.0, 126.0, 125.8, 123.3, 122.0, 117.0, 116.3, 108.6, 57.2, 11.3 (1C is merged with other peaks); **HRMS** (ESI) m/z : calcd for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 403.1475; found, 403.1494;



1,1,1-trifluoro-*N*-(2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)methanesulfonamide (**3am**)

36 mg (47%), yellowish oil, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.65 (dd, $J = 8.2, 1.2$ Hz, 1H),

7.53–7.46 (m, 2H), 7.44–7.38 (m, 1H), 7.38–7.29 (m, 4H), 7.28–7.21 (m, 2H), 6.90 (d, $J = 2.9$ Hz, 1H), 6.22 (d, $J = 2.9$ Hz, 1H), 2.07 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 139.8, 133.2, 131.6, 129.3, 128.3, 128.1, 127.6, 127.5, 125.9, 125.5, 122.4, 119.7 (q, $J = 323.0$ Hz), 119.1, 116.5, 108.6, 11.1; $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -75.9 (s, 3F); **HRMS** (ESI) m/z : calcd for $\text{C}_{18}\text{H}_{16}\text{F}_3\text{N}_2\text{O}_2\text{S}^+ [\text{M}+\text{H}]^+$, 381.0879; found, 381.0880;




3ap

2,4,6-trimethyl-*N*-(3-methyl-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide

(3ap)

33 mg (37%), yellow powder, **M. p.** = 129–131 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.53–7.47 (m, 2H), 7.43–7.37 (m, 1H), 7.36–7.31 (m, 3H), 7.14–7.06 (m, 2H), 6.96 (dt, $J = 7.6, 1.1$ Hz, 1H), 6.89 (d, $J = 2.8$ Hz, 1H), 6.82 (s, 2H), 5.97 (d, $J = 2.9$ Hz, 1H), 2.45 (s, 6H), 2.21 (s, 3H), 2.07 (s, 3H), 1.72 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 142.1, 140.0, 139.3, 138.9, 135.9, 134.2, 131.9, 129.2, 127.4, 127.2, 127.1, 126.7, 125.5, 125.3, 122.0, 116.1, 115.7, 109.2, 22.9, 20.8, 20.5, 10.9; **HRMS** (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_2\text{S}^+ [\text{M}+\text{H}]^+$, 445.1944; found, 445.1952;




3aq

2,4,6-trimethyl-*N*-(4-methyl-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide

(3aq)

53 mg (59%), brown foam, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.54–7.46 (m, 2H), 7.43–7.37 (m, 2H), 7.35–7.30 (m, 2H), 7.19 (br s, 1H), 7.01 (dd, $J = 8.3, 2.2$ Hz, 1H), 6.96 (d, $J = 2.1$ Hz, 1H), 6.84 (d, $J = 2.9$ Hz, 1H), 6.79 (s, 2H), 6.08 (d, $J = 2.9$ Hz, 1H), 2.39 (s, 6H), 2.27 (s, 3H), 2.18 (s, 3H), 1.81 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 142.0, 139.9, 139.3, 134.0, 133.7, 132.5, 131.8, 131.7, 129.2, 128.2, 128.1, 127.3, 126.9, 125.6, 121.7, 120.2, 117.8, 109.0, 22.8, 20.8, 20.7, 10.9; **HRMS** (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_2\text{S}^+ [\text{M}+\text{H}]^+$, 445.1944; found, 445.1962;




3ar

2,4,6-trimethyl-*N*-(5-methyl-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide

(3ar)


66 mg (74%), brown powder, **M. p.** = 148–149 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.54–7.45 (m, 2H), 7.44–7.37 (m, 1H), 7.36–7.30 (m, 3H), 7.27 (br s, 1H), 7.03 (d, *J* = 7.7 Hz, 1H), 6.88 (dd, *J* = 7.8, 1.8 Hz, 1H), 6.85 (d, *J* = 2.9 Hz, 1H), 6.80 (s, 2H), 6.11 (d, *J* = 2.9 Hz, 1H), 2.42 (s, 6H), 2.30 (s, 3H), 2.19 (s, 3H), 1.83 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 142.1, 139.9, 139.3, 137.4, 134.9, 133.9, 131.8, 130.9, 129.2, 127.3, 127.0, 125.6, 124.78, 124.75, 121.7, 120.1, 117.5, 109.1, 22.7, 21.3, 20.8, 10.9; **HRMS** (ESI) *m/z*: calcd for C₂₇H₂₉N₂O₂S⁺ [M+H]⁺, 445.1944; found, 445.1964;

**3as**

N-(4-fluoro-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide

(3as)


64 mg (71%), yellowish foam, **¹H NMR** (400 MHz, CDCl₃): δ 7.55–7.47 (m, 3H), 7.45–7.39 (m, 1H), 7.35–7.29 (m, 2H), 7.21 (br s, 1H), 6.92 (ddd, *J* = 9.0, 8.0, 3.0 Hz, 1H), 6.88–6.83 (m, 2H), 6.78 (s, 2H), 6.08 (d, *J* = 2.9 Hz, 1H), 2.36 (s, 6H), 2.18 (s, 3H), 1.78 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 159.4 (d, *J* = 244.2 Hz), 142.2, 139.7, 139.3, 133.7, 131.8, 131.0 (d, *J* = 2.8 Hz), 130.7 (d, *J* = 8.5 Hz), 129.3, 127.5, 127.1, 125.6, 122.6 (d, *J* = 8.6 Hz), 122.0, 117.6 (d, *J* = 22.1 Hz), 116.9, 114.1 (d, *J* = 22.3 Hz), 108.6, 22.8, 20.8, 10.8; **¹⁹F NMR** (376 MHz, CDCl₃): δ -118.2 (m, 1F); **HRMS** (ESI) *m/z*: calcd for C₂₆H₂₆FN₂O₂S⁺ [M+H]⁺, 449.1694; found, 449.1714;

**3at**

N-(4-chloro-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide

(3at)


57 mg (61%), yellow powder, **M. p.** = 136–137 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.54–7.48 (m, 2H), 7.47–7.39 (m, 2H), 7.35–7.30 (m, 2H), 7.27 (br s, 1H), 7.19–7.12 (m, 2H), 6.86 (d, *J* = 2.9 Hz, 1H), 6.81 (s, 2H), 6.10 (d, *J* = 2.9 Hz, 1H), 2.40 (s, 6H), 2.20 (s, 3H), 1.83 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 142.4, 139.7, 139.2, 133.8, 133.6, 131.9, 130.9, 129.7, 129.3, 129.2, 127.5, 127.4, 127.2, 125.7, 122.1, 120.9, 116.5, 108.8, 22.8, 20.8, 10.9; **HRMS** (ESI) *m/z*: calcd for C₂₆H₂₆ClN₂O₂S⁺ [M+H]⁺, 465.1398; found, 465.1400;



3au

N-(4-bromo-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide
(**3au**)


54 mg (53%), brown powder, **M. p.** = 157–158 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.54–7.47 (m, 2H), 7.45–7.39 (m, 1H), 7.39–7.35 (m, 1H), 7.34–7.29 (m, 3H), 7.29 (s, 1H), 7.26 (br s, 1H), 6.86 (d, *J* = 2.9 Hz, 1H), 6.82 (s, 2H), 6.10 (d, *J* = 2.9 Hz, 1H), 2.41 (s, 6H), 2.20 (s, 3H), 1.85 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 142.5, 139.7, 139.2, 134.4, 133.8, 133.6, 132.0, 130.4, 129.9, 129.3, 127.5, 127.3, 125.7, 122.1, 121.0, 116.8, 116.4, 108.8, 22.8, 20.8, 11.0; **HRMS** (ESI) *m/z*: calcd for C₂₆H₂₆BrN₂O₂S⁺ [M+H]⁺, 509.0893; found, 509.0921;



3av

N-(4-cyano-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide
(**3av**)

69 mg (76%), brown powder, **M. p.** = 177–178 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.55 (br s, 1H), 7.54–7.49 (m, 2H), 7.48–7.40 (m, 4H), 7.37–7.31 (m, 2H), 6.91 (d, *J* = 2.9 Hz, 1H), 6.89 (s, 2H), 6.17 (d, *J* = 2.9 Hz, 1H), 2.50 (s, 6H), 2.24 (s, 3H), 1.94 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 143.1, 139.7, 139.5, 139.2, 134.9, 133.2, 132.2, 131.6, 129.4, 127.7, 127.60, 127.55, 125.8, 122.6, 118.8, 117.6, 115.1, 108.6, 106.6, 22.7, 20.9, 11.0; **HRMS** (ESI) *m/z*: calcd for C₂₇H₂₆N₃O₂S⁺ [M+H]⁺, 456.1740; found, 456.1747;




3aw

methyl 3-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)-4-((2,4,6-trimethylphenyl)sulfonamido)benzoate
(**3aw**)


67 mg (68%), brown powder, **M. p.** = 144–145 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.89–7.82 (m, 2H), 7.55–7.48 (m, 3H), 7.46–7.39 (m, 2H), 7.37–7.33 (m, 2H), 6.90 (d, *J* = 2.9 Hz, 1H), 6.85 (s, 2H), 6.17 (d, *J* = 2.9 Hz, 1H), 3.85 (s, 3H), 2.49 (s, 6H), 2.22 (3H), 1.93 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 166.6, 142.7, 139.7, 139.6, 139.2, 133.4, 132.7, 132.1, 129.3, 129.2, 127.5, 127.4,

126.6, 125.7, 125.0, 122.2, 117.1, 116.4, 108.9, 51.9, 22.7, 20.9, 11.0; **HRMS** (ESI) m/z : calcd for $C_{28}H_{29}N_2O_4S^+$ $[M+H]^+$, 489.1843; found, 489.1861;




N-(4-methoxy-2-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide (**3ax**)

70 mg (76%), yellowish crystal, **M. p.** = 127–128 °C; **¹H NMR** (400 MHz, $CDCl_3$): δ 7.55–7.47 (m, 3H), 7.43–7.37 (m, 1H), 7.34–7.29 (m, 2H), 7.11 (br s, 1H), 6.83 (d, J = 2.9 Hz, 1H), 6.78 (dd, J = 8.9, 3.0 Hz, 1H), 6.74 (s, 2H), 6.68 (d, J = 3.0 Hz, 1H), 6.05 (d, J = 2.9 Hz, 1H), 3.75 (s, 3H), 2.32 (s, 6H), 2.15 (s, 3H), 1.74 (s, 3H); **¹³C NMR** (100 MHz, $CDCl_3$): δ 156.5, 141.9, 139.8, 139.3, 133.9, 131.7, 130.6, 129.3, 127.9, 127.3, 126.9, 125.5, 123.3, 121.7, 118.0, 116.2, 112.7, 108.8, 55.4, 22.9, 20.8, 10.9; **HRMS** (ESI) m/z : calcd for $C_{27}H_{29}N_2O_3S^+$ $[M+H]^+$, 461.1893; found, 461.1905;



2,4,6-trimethyl-*N*-(3-(2-methyl-1-phenyl-1*H*-pyrrol-3-yl)pyridin-2-yl)benzenesulfonamide (**3ay**)


75 mg (87%), brown oil, **¹H NMR** (400 MHz, $CDCl_3$): δ 8.02 (br s, 1H), 7.64 (br s, 1H), 7.53–7.46 (m, 2H), 7.45–7.39 (m, 2H), 7.39–7.35 (m, 2H), 6.93 (s, 2H), 6.88 (d, J = 3.0 Hz, 1H), 6.87–6.83 (m, 1H), 6.26 (d, J = 2.9 Hz, 1H), 2.75 (s, 6H), 2.72 (s, 3H), 2.09 (s, 3H); **¹³C NMR** (100 MHz, $CDCl_3$): δ 150.1, 146.1, 142.2, 140.0, 139.7, 139.0, 134.3, 131.6, 129.2, 127.5, 127.4, 125.8, 122.2, 119.2, 117.7, 115.9, 108.6, 22.8, 20.9, 11.3; **HRMS** (ESI) m/z : calcd for $C_{25}H_{26}N_3O_2S^+$ $[M+H]^+$, 432.1740; found, 432.1747;



N-(2-(2,4-dimethyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide (**3az**)

16 mg (18%), light red powder, **M. p.** = 61–63 °C; **¹H NMR** (400 MHz, $CDCl_3$): δ 7.55 (dd, J = 8.2, 1.2 Hz, 1H), 7.51–7.45 (m, 2H), 7.40–7.35 (m, 1H), 7.34–7.29 (m, 2H), 7.22 (ddd, J = 8.2, 7.1, 1.9 Hz, 1H), 7.14–7.03 (m, 3H), 6.80 (s, 2H), 6.68 (d, J = 1.1 Hz, 1H), 2.41 (s, 6H), 2.19 (s, 3H), 1.82 (s, 3H), 1.76 (d, J = 1.1 Hz, 3H); **¹³C NMR** (100 MHz, $CDCl_3$): δ 142.2, 140.0, 139.2,


135.6, 134.0, 131.9, 131.8, 129.2, 127.8, 127.0, 126.7, 126.6, 125.5, 123.9, 119.8, 119.0, 118.2, 118.0, 22.7, 20.8, 11.2, 10.2; **HRMS** (ESI) m/z : calcd for $C_{27}H_{29}N_2O_2S^+$ $[M+H]^+$, 445.1944; found, 445.1969;



3aA

N-(2-(2-ethyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide (**3aA**)


44 mg (49%), brown powder, **M. p.** = 141–143 °C; **¹H NMR** (400 MHz, $CDCl_3$): δ 7.53–7.47 (m, 2H), 7.45–7.35 (m, 4H), 7.28 (br s, 1H), 7.22–7.15 (m, 2H), 7.04 (td, $J = 7.4, 1.3$ Hz, 1H), 6.87 (s, 2H), 6.81 (d, $J = 2.9$ Hz, 1H), 6.06 (d, $J = 2.9$ Hz, 1H), 2.50 (s, 6H), 2.37 (q, $J = 7.5$ Hz, 2H), 2.25 (s, 3H), 0.70 (t, $J = 7.5$ Hz, 3H); **¹³C NMR** (100 MHz, $CDCl_3$): δ 142.3, 140.2, 139.3, 135.5, 134.1, 133.3, 132.0, 131.4, 129.3, 127.68, 127.65, 127.3, 126.2, 123.5, 122.4, 118.4, 116.8, 109.1, 22.9, 20.9, 17.9, 14.5; **HRMS** (ESI) m/z : calcd for $C_{27}H_{29}N_2O_2S^+$ $[M+H]^+$, 445.1944; found, 445.1949;



3aB

2,4,6-trimethyl-*N*-(2-(1-phenyl-2-propyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3aB**)


20 mg (22%), brown foam, **¹H NMR** (400 MHz, $CDCl_3$): δ 7.53–7.47 (m, 2H), 7.45–7.33 (m, 4H), 7.26 (br s, 1H), 7.21–7.15 (m, 2H), 7.04 (td, $J = 8.0, 1.2$ Hz, 1H), 6.87 (s, 2H), 6.81 (d, $J = 2.9$ Hz, 1H), 6.05 (d, $J = 2.9$ Hz, 1H), 2.50 (s, 6H), 2.32 (t, $J = 8.0$ Hz, 2H), 2.25 (s, 3H), 1.12–1.00 (m, 2H), 0.55 (t, $J = 7.3$ Hz, 3H); **¹³C NMR** (100 MHz, $CDCl_3$): δ 142.3, 140.2, 139.3, 135.4, 134.1, 132.0, 131.8, 131.4, 129.3, 127.63, 127.59, 127.3, 126.1, 123.5, 122.5, 118.3, 117.3, 109.1, 26.6, 22.9, 20.9, 13.7 (1C is merged with other peaks); **HRMS** (ESI) m/z : calcd for $C_{28}H_{31}N_2O_2S^+$ $[M+H]^+$, 459.2101; found, 459.2100;




3aC

2,4,6-trimethyl-*N*-(2-(2-pentyl-1-phenyl-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3aC**)


28 mg (29%), yellowish oil, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.53–7.46 (m, 2H), 7.45–7.39 (m, 2H), 7.38–7.33 (m, 2H), 7.27 (br s, 1H), 7.21–7.15 (m, 2H), 7.03 (td, $J = 7.4, 1.2$ Hz, 1H), 6.87 (s, 2H), 6.80 (d, $J = 2.9$ Hz, 1H), 6.05 (d, $J = 2.9$ Hz, 1H), 2.49 (s, 6H), 2.31 (t, $J = 8.0$ Hz, 2H), 2.24 (s, 3H), 1.09–1.00 (m, 2H), 1.00–0.86 (m, 4H), 0.64 (t, $J = 7.0$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 142.2, 140.2, 139.3, 135.4, 134.2, 132.0, 131.3, 129.2, 127.6, 127.4, 126.1, 123.5, 122.4, 118.4, 117.2, 109.1, 31.2, 29.1, 24.4, 22.9, 21.8, 20.9, 13.7 (2C are merged with other peaks); **HRMS** (ESI) m/z : calcd for $\text{C}_{30}\text{H}_{35}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 487.2414; found, 487.2404;



2,4,6-trimethyl-*N*-(2-(2-methyl-1-(*o*-tolyl)-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3bc**)
59 mg (66%), yellowish foam, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.42–7.29 (m, 5H), 7.27–7.23 (m, 1H), 7.19–7.12 (m, 2H), 7.02 (td, $J = 7.4, 1.2$ Hz, 1H), 6.85 (s, 2H), 6.71 (d, $J = 2.8$ Hz, 1H), 6.16 (d, $J = 2.8$ Hz, 1H), 2.50 (s, 6H), 2.22 (s, 3H), 2.08 (s, 3H), 1.76 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 142.3, 139.3, 138.9, 135.9, 135.3, 133.8, 131.9, 131.3, 130.9, 128.6, 127.9, 127.6, 127.5, 127.1, 126.6, 123.4, 121.7, 117.9, 116.3, 108.6, 22.8, 20.9, 17.2, 10.3; **HRMS** (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 445.1944; found, 445.1969




2,4,6-trimethyl-*N*-(2-(2-methyl-1-(*m*-tolyl)-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3cc**)
55 mg (62%), yellowish powder, **M. p.** = 144–145 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.48 (dd, $J = 8.2, 1.2$ Hz, 1H), 7.37 (t, $J = 7.6$ Hz, 1H), 7.31 (br s, 1H), 7.24–7.11 (m, 5H), 7.06 (td, $J = 7.4, 1.3$ Hz, 1H), 6.85 (d, $J = 2.9$ Hz, 1H), 6.81 (s, 2H), 6.11 (d, $J = 2.9$ Hz, 1H), 2.45 (s, 3H), 2.42 (s, 6H), 2.20 (s, 3H), 1.83 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 142.1, 139.9, 139.3, 135.2, 134.0, 131.8, 131.2, 129.0, 128.1, 127.9, 127.5, 127.0, 126.3, 124.0, 122.7, 121.8, 119.6, 117.4, 108.8, 22.8, 21.4, 20.8, 10.9 (1C is merged with other peaks); **HRMS** (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 445.1944; found, 445.1966




2,4,6-trimethyl-*N*-(2-(2-methyl-1-(*p*-tolyl)-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3dc**)

50 mg (56%), yellowish oil, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.48 (dd, $J = 8.1, 1.2$ Hz, 1H), 7.34–7.27 (m, 3H), 7.23–7.13 (m, 4H), 7.05 (td, $J = 7.5, 1.3$ Hz, 1H), 6.83 (d, $J = 2.9$ Hz, 1H), 6.80 (s, 2H) 6.11 (d, $J = 2.9$ Hz, 1H), 2.44 (s, 3H), 2.42 (s, 6H), 2.19 (s, 3H), 1.82 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 142.1, 139.3, 137.4, 137.3, 135.2, 133.9, 131.8, 131.2, 129.8, 127.9, 127.5, 127.1, 125.5, 124.0, 121.9, 119.6, 117.3, 108.7, 22.8, 21.0, 20.8, 10.9; **HRMS** (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 445.1944; found, 445.1964;




N-(2-(1-(4-fluorophenyl)-2-methyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide
(**3ec**)

45 mg (50%), yellowish crystal, **M. p.** = 137–139 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.44 (dd, $J = 8.1, 1.2$ Hz, 1H), 7.34–7.28 (m, 2H), 7.25 (br s, 1H), 7.22–7.16 (m, 3H), 7.14 (dd, $J = 7.6, 1.7$ Hz, 1H), 7.06 (td, $J = 7.4, 1.2$ Hz, 1H), 6.84–6.79 (m, 3H), 6.13 (d, $J = 2.9$ Hz, 1H), 2.44 (s, 6H), 2.21 (s, 3H), 1.83 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 161.7 (d, $J = 247.5$ Hz), 142.2, 139.3, 136.0 (d, $J = 3.2$ Hz), 135.2, 134.0, 131.9, 131.2, 127.64, 127.60, 127.4 (d, $J = 8.6$ Hz), 127.2, 123.9, 121.9, 119.4, 117.6, 116.2 (d, $J = 22.7$ Hz), 109.1, 22.8, 20.8, 10.8; $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -114.0 (s, 1F); **HRMS** (ESI) m/z : calcd for $\text{C}_{26}\text{H}_{26}\text{FN}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 449.1694; found, 449.1719;




N-(2-(1-(4-chlorophenyl)-2-methyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide
(**3fc**)

68 mg (73%), white powder, **M. p.** = 129–130 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.50–7.45 (m, 2H), 7.44 (dd, $J = 8.1, 1.2$ Hz, 1H), 7.31–7.26 (m, 2H), 7.23 (br s, 1H), 7.19 (td, $J = 7.8, 1.8$ Hz, 1H), 7.13 (dd, $J = 7.6, 1.7$ Hz, 1H), 7.06 (td, $J = 7.4, 1.2$ Hz, 1H), 6.83 (d, $J = 2.9$ Hz, 1H), 6.81 (s, 2H), 6.14 (d, $J = 2.9$ Hz, 1H), 2.43 (s, 6H), 2.20 (s, 3H), 1.84 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 142.2, 139.2, 138.4, 135.2, 133.9, 133.1, 131.9, 131.2, 129.4, 127.7, 127.5, 127.0, 126.8, 124.0, 121.7, 119.5, 118.0, 109.4, 22.8, 20.8, 10.9; **HRMS** (ESI) m/z : calcd for $\text{C}_{26}\text{H}_{26}\text{ClN}_2\text{O}_2\text{S}^+$ $[\text{M}+\text{H}]^+$, 465.1398; found, 465.1405;




N-(2-(1-(4-bromophenyl)-2-methyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide (**3gc**)

58 mg (57%), offwhite powder, **M. p.** = 147–148 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.65–7.60 (m, 2H), 7.44 (dd, *J* = 8.1, 1.2 Hz, 1H), 7.25–7.16 (m, 4H), 7.13 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.06 (td, *J* = 7.4, 1.3 Hz, 1H), 6.83 (d, *J* = 2.9 Hz, 1H), 6.81 (s, 2H), 6.14 (d, *J* = 2.9 Hz, 1H), 2.43 (s, 6H), 2.20 (s, 3H), 1.84 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 142.2, 139.2, 138.9, 135.2, 133.9, 132.4, 131.9, 131.2, 127.7, 127.5, 127.1, 126.9, 124.0, 121.6, 121.0, 119.5, 118.0, 109.5, 22.7, 20.8, 10.9; **HRMS** (ESI) *m/z*: calcd for C₂₆H₂₆BrN₂O₂S⁺ [M+H]⁺, 509.0893; found, 509.0897;



2,4,6-trimethyl-*N*-(2-(2-methyl-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3hc**)


21 mg (21%), yellowish powder, **M. p.** = 175–176 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.82–7.73 (m, 2H), 7.51–7.45 (m, 2H), 7.42 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.23–7.17 (m, 2H), 7.15 (dd, 7.5, 1.7 Hz, 1H), 7.07 (td, *J* = 7.4, 1.2 Hz, 1H), 6.89 (d, *J* = 3.0 Hz, 1H), 6.82 (s, 2H), 6.19 (d, *J* = 2.9 Hz, 1H), 2.44 (s, 6H), 2.21 (s, 3H), 1.90 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ 142.8, 142.3, 139.3, 135.2, 134.0, 131.9, 131.2, 129.3 (q, *J* = 32.7 Hz), 127.8, 127.3, 127.0, 126.6 (q, *J* = 3.6 Hz), 125.6, 124.0, 123.8 (q, *J* = 272.2 Hz), 121.6, 119.5, 118.7, 110.1, 22.8, 20.8, 11.1; **¹⁹F NMR** (376 MHz, CDCl₃): δ -62.2 (s, 3F); **HRMS** (ESI) *m/z*: calcd for C₂₇H₂₆F₃N₂O₂S⁺ [M+H]⁺, 499.1662; found, 499.1667



2,4,6-trimethyl-*N*-(2-(2-methyl-1-(4-(trifluoromethoxy)phenyl)-1*H*-pyrrol-3-yl)phenyl)benzenesulfonamide (**3ic**)

58 mg (56%), yellow foam, **¹H NMR** (400 MHz, CDCl₃): δ 7.43 (dd, *J* = 8.1, 1.2 Hz, 1H),



7.41–7.33 (m, 4H), 7.23–7.17 (m, 2H), 7.14 (dd, $J = 7.6, 1.7$ Hz, 1H), 7.06 (td, $J = 7.4, 1.2$ Hz, 1H), 6.85 (d, $J = 2.9$ Hz, 1H), 6.82 (s, 2H), 6.15 (d, $J = 2.9$ Hz, 1H), 2.44 (s, 6H), 2.21 (s, 3H), 1.86 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 148.0, 142.3, 139.3, 138.4, 135.2, 134.0, 131.9, 131.2, 127.7, 127.4, 127.1, 127.0, 124.0, 121.83, 121.8, 120.4 (q, $J = 257.8$ Hz), 119.5, 118.1, 109.6, 22.8, 20.8, 11.0; $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -57.8 (s, 3F); **HRMS** (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{26}\text{F}_3\text{N}_2\text{O}_3\text{S}^+$ $[\text{M}+\text{H}]^+$, 515.1611; found, 515.1630;






N-(2-(1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide (**3jc**)

60 mg (65%), yellowish foam, $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.47 (dd, $J = 8.2, 1.2$ Hz, 1H), 7.33 (br s, 1H), 7.27–7.23 (m, 2H), 7.21–7.16 (m, 1H), 7.14 (dd, $J = 7.6, 1.7$ Hz, 1H), 7.05 (td, $J = 7.4, 1.3$ Hz, 1H), 7.03–6.98 (m, 2H), 6.81 (d, $J = 2.9$ Hz, 1H), 6.80 (s, 2H), 6.10 (d, $J = 2.9$ Hz, 1H), 3.88 (s, 3H), 2.42 (s, 6H), 2.20 (s, 3H), 1.80 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 158.8, 142.1, 139.3, 135.1, 133.9, 132.9, 131.8, 131.2, 127.9, 127.5, 127.3, 127.0, 123.9, 122.0, 119.5, 117.0, 114.3, 108.5, 55.5, 22.8, 20.8, 10.8; **HRMS** (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_3\text{S}^+$ $[\text{M}+\text{H}]^+$, 461.1893; found, 461.1906;



Copies of NMR spectra of unknown substrates and products















-107.342
 -107.362
 -107.374
 -107.387
 -107.406

















































































7.724
7.721
7.717
7.708
7.703
7.699
7.687
7.684
7.680
7.604
7.501
7.498
7.495
7.486
7.480
7.475
7.471
7.466
7.461
7.458
7.413
7.410
7.407
7.396
7.392
7.386
7.380
7.376
7.372
7.362
7.358
7.340
7.336
7.331
7.322
7.316
7.314
7.314
7.269
7.256
7.252
7.249
7.249
7.236
7.231
7.158
7.143
7.138
7.123
7.119
7.099
7.096
7.081
7.078
7.062
7.059
6.816
6.808
5.842
5.834
1.827



3ab

¹H NMR


(400 MHz, in CDCl₃)



139.821
139.355
135.036
132.819
131.219
129.217
128.824
127.794
127.747
127.343
127.071
125.687
124.152
121.851
115.391
117.079
708.664

77.317
76.989
76.680


10.973







3ab



¹³C NMR

(100 MHz, in CDCl₃)












7.898
7.893
7.879
7.874
7.860
7.856
7.874
7.572
7.554
7.551
7.525
7.521
7.519
7.505
7.500
7.496
7.488
7.488
7.485
7.481
7.475
7.467
7.465
7.462
7.456
7.448
7.444
7.444
7.425
7.422
7.418
7.408
7.403
7.398
7.392
7.388
7.383
7.382
7.374
7.371
7.366
7.362
7.346
7.316
7.311
7.208
7.205
7.197
7.193
7.189
7.186
7.177
7.173
7.169
7.167
7.158
7.154
7.077
7.074
7.059
7.055
7.040
7.037
7.020
7.016
7.013
6.995
6.992
6.976
6.959
6.944
6.104
1.907




3af
¹H NMR
(400 MHz, in CDCl₃)




160.150
157.589
139.958
135.226
135.142
134.660
131.301
130.941
129.220
127.683
127.498
127.357
127.270
127.137
127.026
125.829
124.199
124.161
124.003
122.024
118.467
117.036
117.014
116.603
108.024
77.317
76.389
76.061
11.012




3af
¹³C NMR
(100 MHz, in CDCl₃)







3af
¹⁹F NMR
 (376 MHz, in CDCl₃)






7.665
 7.663
 7.649
 7.645
 7.510
 7.508
 7.504
 7.496
 7.494
 7.490
 7.486
 7.484
 7.474
 7.471
 7.469
 7.418
 7.415
 7.412
 7.402
 7.396
 7.391
 7.381
 7.378
 7.376
 7.372
 7.367
 7.359
 7.358
 7.355
 7.352
 7.347
 7.333
 7.330
 7.328
 7.326
 7.312
 7.308
 7.306
 7.302
 7.287
 7.283
 7.255
 7.185
 7.182
 7.166
 7.163
 7.148
 7.144
 6.929
 6.890
 6.883
 6.202
 6.185
 2.074





3aj
¹H NMR
 (400 MHz, in CDCl₃)













3ak
 ^{13}C NMR
 (100 MHz, in CDCl_3)







3al
 ^1H NMR
 (400 MHz, in CDCl_3)





























3as



¹⁹F NMR



(376 MHz, in CDCl₃)




































































3hc

¹⁹F NMR

(376 MHz, in CDCl₃)



7.439
7.436
7.418
7.415
7.372
7.367
7.364
7.256
7.216
7.213
7.186
7.174
7.174
7.154
7.150
7.135
7.131
7.083
7.080
7.064
7.061
6.851
6.843
6.823
6.820
6.151



3ic

¹H NMR

(400 MHz, in CDCl₃)

